Abstract:Abstract Background and objectives: Hepatocellular carcinoma (HCC) is the primary liver malignancy with an extremely low survival rate. HCC progression is frequently associated with accelerated glucose consumption that confers growth advantage to tumor cell through two essential metabolic pathways - glycolysis and the pentose phosphate pathway (PPP). Glycolysis utilizes glucose for ATP production, while the PPP converts glycolytic intermediates to generate NADPH, the cellular antioxidant, and ribose-5-phophate, the nucleotide precursor. Although glycolysis has been extensively studied in HCC, how PPP supports HCC growth remains largely unknown. Our study aims at delineating the clinical significance, regulation and functions of PPP in HCC development and explore the therapeutic potential of PPP inhibitors for HCC therapy. Methods: The expression and abundance of the the PPP genes were examined in 16 pairs of human HCC tumors and adjacent non-tumors by transcriptome sequencing. Level of reactive oxygen species (ROS) and glucose uptake were measured by CM-H2DCFDA and 2-NBDG stainings, respectively. Metabolomics study was performed with CE-TOF-MS analysis. Metabolic flux analysis was conducted using UPLC-MS/MS. Results: Transcriptome sequencing data showed that enzymes in the PPP were frequently upregulated in HCC. Transketolase (TKT), the gene encodes the reversible enzyme connecting PPP and glycolysis, is the most abundant and most overexpressed PPP gene in HCC. Overexpression of TKT was confirmed in an expanded sample cohort at the mRNA and protein level. Meanwhile, TKT overexpression was significantly correlated with venous invasion, microsatellite formation, tumor size and absence of tumor encapsulation. Notably, TKT expression was controlled by NRF2/KEAP1/BACH1 pathway, which is a major transcription regulator for redox homeostasis. CHIP assay revealed that NRF2 and BACH1 competitively bound to the same antioxidant responsive elements (ARE) in TKT. Functionally, knockdown of TKT in HCC cells retarded cell growth, attenuated glucose uptake and NADPH production, increased intracellular ROS, and induced oxidative stress-associated cell cycle delay. In line with these findings, knockdown of TKT greatly suppressed tumor growth in vivo. Metabolomics and metabolic flux analysis revealed that loss of TKT disrupted the PPP and subsequently reduced NADPH production. Intriguingly, genetic knockdown and pharmacological inhibition of TKT enhanced the efficacy of Sorafenib, the only FDA-approved drug for HCC treatment, both in vitro and in vivo. Conclusion: Our study suggested the clinical significance of TKT in HCC and illustrated the anti-oxidative role of TKT in HCC progression. We also proposed that disrupting the metabolic machinery by TKT inhibition might be a novel therapeutic strategy for HCC treatment. Citation Format: Ming Jing Xu, Kit Ho Lai, Shu Hai Lin, Pui Wah Tse, David Kung Chun Chiu, Hui Yu Koh, Cheuk Ting Law, Chun Ming Wong, Zong Wei Cai, Carmen Chak Lui Wong, Irene Oi Lin Ng. Targeting pentose phosphate pathway (PPP) represents a novel therapeutic strategy for hepatocellular carcinoma (HCC) treatment. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1058.

Abstract 341: the Role of Telomere Protective Protein TPP1 in Hepatocellular Carcinoma

Mutation Analysis of Novel Human Liver-Related Putative Tumor Suppressor Gene in Hepatocellular Carcinoma

Over-expression of LPTS-L in Hepatocellular Carcinoma Cell Line SMMC-7721 Induces Crisis

TPP1 Regulates hTERT Expression and Predicts Early Malignant Event and Prognosis of Cervical Cancer

TPP1 is Associated with Risk of Advanced Precursors and Cervical Cancer Survival

Abstract 4607: G1/S Transition-Related Gene Mutations Associated with Survival of Hepatocellular Carcinoma Patients

Abstract 1058: Targeting Pentose Phosphate Pathway (PPP) Represents a Novel Therapeutic Strategy for Hepatocellular Carcinoma (HCC) Treatment

Protein tyrosine phosphatase non-receptor II: A possible biomarker of poor prognosis and mediator of immune evasion in hepatocellular carcinoma

Telomere-Binding Protein TPP1 Modulates Telomere Homeostasis and Confers Radioresistance to Human Colorectal Cancer Cells

Abstract 1983: TP53 Mutations in Hepatocellular Carcinoma: Association with Survival and Stem Cell-Like Gene Expression Traits

TAF1B depletion leads to apoptotic cell death by inducing nucleolar stress and activating p53-miR-101 circuit in hepatocellular carcinoma

Abstract 4389: TSC1/2 Mutations Define a Molecular Subset of HCC with Aggressive Behavior and Treatment Implication

High-expressed PTPN1 Promotes Tumor Proliferation Signature in Human Hepatocellular Carcinoma

TPR is a Prognostic Biomarker and Potential Therapeutic Target Associated with Immune Infiltration in Hepatocellular Carcinoma.

Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma

Abstract 4425: Comprehensive Study of TGF-β Pathway-Driven Functional Molecular Characterization of Human Hepatocellular Cancer

Long Noncoding Rna Tp53tg1 Suppresses The Growth And Metastasis Of Hepatocellular Carcinoma By Regulating The Prdx4/Beta-Catenin Pathway

Abstract 1515: NCOA3 Promotes Tumor Growth by Activating Telomerase Reverse Transcriptase and Predicts Poor Prognosis in Hepatocellular Carcinoma

Data from Association of Specific Genotypes in Metastatic Suppressor HTPAP with Tumor Metastasis and Clinical Prognosis in Hepatocellular Carcinoma

Abstract 1255: Identification of Mutational Landscape Predicting Efficacy of Immune Checkpoint Blockades and Recurrent Mutations Related to High Tumor Mutational Burden in Hepatocellular Carcinoma by Next Generation Sequencing

Arare Variant P507l In Tpp1 Interrupts Tpp1-Tin2 Interaction, Influences Telomere Length, And Confers Colorectal Cancer Risk In Chinese Population